Posts Tagged With 'polmone'

Be MUT-ual Days

Be MUT-ual DaysBe MUT-ual DaysBe MUT-ual Days

Oncogene driven Cancers: the new paradigm

Posted by press m d, y No Comments »
Read More

How to feel better with a ‘trick’ 2019

Come star meglio con un "trucco" edizione 2019How to feel better with a 'trick' 2019

“How to feel better with a ‘trick’” 2019

For the tenth consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies.

Posted by admin m d, y No Comments »
Read More

In Famiglia All’Improvviso

In Famiglia All'ImprovvisoIn Famiglia All'ImprovvisoIn Famiglia All'Improvviso

Posted by press m d, y No Comments »
Read More



Posted by press m d, y No Comments »
Read More

How to feel better with a ‘trick’ 2017

Come star meglio con un "trucco" edizione 2017How to feel better with a 'trick' 2017

“How to feel better with a ‘trick’” 2017

For the eighth consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies.

Posted by press m d, y No Comments »
Read More

News from WALCE

Segnalati da WALCENews from WALCE

- INTERNATIONAL SYMPOSIUM – Resolving Cancer Heterogeneity: Drawing new horizons in precision medicine

Save the Date (PDF) | Program Brochure (PDF)

- Prof Silvia Novello, current President of WALCE, at ”A Symposium: Cancer in Women”, in Petah Tikva (Israel) – Tuesday 10th March 2015.


Lung Cancer Awareness Month

TOPIC:  Tobacco Use and Lung Cancer  – Laymen’s Summary and Main Message

FOR MORE INFORMATION VISIT: Prevent lung cancer: It is never too late to stop smoking!

November is Lung Cancer Awareness Month in many countries.  We are asking you to help educate the media, the public, and even your own social circles about the health threat that lung cancer poses, and the hope that new treatments are providing to change the outcome for many patients.

Tobacco Use and Lung Cancer  – Lay Summary and Main Messages to Communicate to Media and the Public.

  • Lung Cancer is the #1 cancer killer in the world, killing more people than breast, colorectal and prostate cancers combined.
  • Although smoking is by far the largest known cause of lung cancer, anyone can get lung cancer.
  • 80-90% of lung cancer deaths could be completely avoided if people did not smoke cigarettes.
  • If you do smoke, it is never too late to stop.  Stopping smoking reduces the risk of developing lung cancer.
  • In those diagnosed with lung cancer, continued smoking will interfere with the effectiveness of your cancer treatment.  The sooner you stop the better off you will be.
  • Most people who smoke are addicted to nicotine and would benefit from using approved stop smoking medications and receiving counseling to help support their quit attempt.
  • Approved stop smoking medications include: nicotine patches, gum, lozenge, inhaler, and nasal spray; Chantix and Zyban.  As of today, e-cigarettes are not an approved stop smoking medication.
  • Studies have shown that many attempts and many different methods are often needed to finally quit smoking.  If you have tried before, keep trying.
  • Don’t be bashful, ask your doctor for help to stop smoking.

Ask your interviewer:

  • Would you like to speak to a patient who has successfully quit?
  • Would you like to speak to another member of the multi-disciplinary team involved here at our institution? A pathologist, surgeon, nurse, etc.
  • Would you like to speak to additional experts who represent the International Association for the Study of Lung Cancer (IASLC), which is the only international association dedicated to the study of lung cancer?  If so, please contact Rob Mansheim ( to be directed to these experts.

Continue the Conversation:

- Copy and use the following badge in your social media profiles and email signatures for the month of November:

-  Follow IASLC on Facebook and Twitter for all the latest details and daily updates about Lung Cancer Awareness Month events and information.  Facebook and Twitter.

- Join the conversation on social media using #LCAM and #LCAM14.

-  View the IASLC key messages for the media on other topics featured during Lung Cancer Awareness Month.

Download the E-Cigarettes and Cancer Patients from IASLC website.

-  Share this list of Advocacy Partners or Advocacy Events with your patients.

Posted by press m d, y No Comments »
Read More

Go out of the Tunnel 2016

Esci dal Tunnel - Edizione 2016Go out of the Tunnel 2016 Esci dal Tunnel - Edizione 2016

Go out of the tunnel. Don’t burn away your future.

A national campaign for prevention and information on the risks of smoking and awareness about lung cancer, addressed to citizens, media and institutions.

WALCE promotes “GO OUT OF THE TUNNEL. DON’T BURN AWAY YOUR FUTURE.”, a national campaign for prevention and information on the risks of smoking and awareness about lung cancer, addressed to citizens, media and institutions.

In 2015 the roadshow toured 5 major Italian cities (Turin, Bari, Milan, Padova and Rome); It started on the World No Tobacco Day, in May, and It ended in November, Lung Cancer Awareness Month. Over 3,000 people visited the Tunnel, involving groups of heterogeneous age: young people, adults and the elderly; during the program, several volunteers helped: 28 Pulmonologists, 6 Oncologists and 1 Radiation Oncologist. More than 1,000 spirometric tests have made. In addition, the Italian Minister of Health, Hon. Beatrice Lorenzin, attended at the final date in Rome.

In 2016, a second edition of the roadshow has been programmed. These are the 4 cities where “Go Out of the Tunnel” has been scheduled this year:

1. PADOVA – May 14/15

2. LECCE – June 4/5

3. MESSINA – October 1/2

4. ROME – November 11/12

A large cigarette butt shaped booth is set up in the main squares of the cities involved. The structure is 3 meters high and 14 meters long and, inside, visitors can find a viable tunnel that provides information about tobacco smoking prevention and raises awareness about lung cancer.

The tunnel interior is divided by different areas:

- an area dedicated to primary prevention where people may consult info-educational booklets and brochures realized by WALCE over the years;

- a medical area where people can do a spirometry test for free, made by a Pulmonologist, and receive the result, dealing directly with the physician.

Posted by press m d, y Comments Off
Read More

News from ESMO 2016

News dall'ESMO 2016News from ESMO 2016

News from the European Society for Medical Oncology Congress

Copenhagen, 7-11 October 2016

- “ESMO 2016 Press Release: Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression” | 09 Oct 2016

“ESMO 2016 Press Release: Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cance” | 09 Oct 2016

Posted by press m d, y No Comments »
Read More

November – Lung Cancer Awareness Month

Novembre – Mese mondiale di sensibilizzazione del Tumore al Polmone November – Lung Cancer Awareness Month

During this month, WALCE carries out various activities to support the patients, to inform and increase the awareness of the public opinion and primary schools pupils and remind to everyone that every 30 seconds a person dies from lung cancer in the world.

The month of November has been declared the Lung Cancer Awareness Month by the Global Lung Cancer Coalition. | | #LCAM

This is an important date to give correct and update information about a disease often overlooked by the media, maybe because still too related to the “stigma of smokers.” Lung cancer is now one of the most difficult cancer to treat: in Italy, it causes every year 35000 deaths and over one million worldwide, and unfortunately numbers are growing. It is estimated that in 2020 Italy will reach 45000 cases and about 51500 in 2030.

WALCE (Women Against Lung Cancer in Europe), created to support, raise the awareness and support women in the fight against lung cancer, but today involved in supporting all patients suffering from this disease and their families, has designed and implemented different activities and initiatives during the month of November.

- “How to feel better with a ‘trick’” 2016

For the sixth consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies.

- “Go out of the Tunnel 2016″

A prevention and information campaign on damages of smoking  and to raise awareness about lung cancer aimed at citizens, media and institutions.

I do not smoke it – we shall try to see things clearly in the smoky speeches


The project named “I do not smoke it – we shall try to see things clearly in the smoky speeches” is going on: an information and awareness campaign on damages of smoking and on the healthy lifestyles, aimed at 10 year-old pupils, consisting of an educational kit for the class.


November – Lung Cancer Awareness Month | Worldwide

Posted by press m d, y No Comments »
Read More

ELF Lung Cancer

ELF Lung CancerELF Lung CancerELF Lung Cancer

The new ERS/ELF lung cancer website is on line:

ELF Lung Cancer

The website has been developed in consultation with people with experience of lung cancer as well as ERS lung cancer healthcare professionals.

It offers:

- Basic information about lung cancer developed with our lung cancer patient advisory group and ERS members working in the field.

- Links to detailed lung cancer information produced by ERS, support organisations and latest research.

- Links to patient information in a range of languages. This an area we would like to add more to over time.

Posted by press m d, y No Comments »
Read More

How to feel better with a ‘trick’ 2016

Come star meglio con un "trucco" edizione 2016How to feel better with a 'trick' 2016

“How to feel better with a ‘trick’” 2016

For the seventh consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies. 

Posted by press m d, y No Comments »
Read More



1st August, #WorldLungCancerDay 2018 | – International Association for the Study of Lung Cancer

Mindfulness-Based Cognitive Therapy for Psychological Distress in Patients With Cancer” | The ASCO – Tue. 17 July 2018

“Living With Squamous Cell Lung Cancer: A Guide for Patients” (PDF)

A new educational booklet, that provides specific information on squamous cell lung cancer to patients and their caregivers, with a focus on the advanced stage of this cancer, is available.

1st August, #WorldLungCancerDay | – International Association for the Study of Lung Cancer

“Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy” | The ASCO – Mon. 25 July 2016

“As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda” | The ASCO – Mon. 25 July 2016

“Do picture warnings on cigarettes increase quit attempts?” | – Mon. 6 June 2016


Press release: Lung Cancer White Paper launched

Brussels, 10 November: A White Paper aimed at tackling unnecessary deaths caused by lung cancer was launched today in the European Parliament (Tuesday, 10 November) and aims to promote greater access to innovative treatment and more efficient organisation of research.

The authors, the European Alliance for Personalised Medicine (EAPM), say that lung cancer patients urgently need action at the highest level. The document is a direct appeal to EU and Member State policymakers, legislators and regulators.

EAPM writes that improvements will “depend primarily on greater collaboration between Member States and across the healthcare sector. The collaboration should include patients, caregivers and patient organisations, who have an indispensable contribution to make”.

Lung cancer is the biggest global killer of all cancers. Fewer than half of newly diagnosed sufferers live beyond a year, with only 16 percent surviving for five years.

It is such a huge killer partly because it is harder to detect in its early stages. By the time a person begins to notice symptoms, it has often spread to other parts of the body and is, therefore, difficult to treat.

The majority of lung cancers in both sexes are caused by smoking, but about 15 percent are not, and the majority of those non-smokers are women, mostly young women.

Lung cancer in women has increased by a staggering 600% over the past 30 years. Today, more are killed each year by lung cancer than they are by breast, ovarian and uterine cancer combined.

Various theories have been posited for this (estrogen as a tumour promoter, is one example) but, put simply, scientists are just not sure.

The Paper adds: “It is clear that physicians need more effective ways to detect and target these cancers. “European Respiratory Society, lung cancer expert Prof. Jean-Paul Sculier, said: “The battle against lung cancer is lagging behind, for example, the fight against breast cancer. One reason is a general lack of funding for research. More research is desperately needed. Another reason is a relative lack of patient advocacy because so many patients die.”

Gordon McVie, EAPM Secretary, said: “More effort is needed in prevention. Public awareness of the disease and the risk factors should be developed, particularly among younger people, women and front-line healthcare professionals.”

Stefania Vallone, from Women Against Lung Cancer, said: “Many citizens are asking: ‘Why does Europe matter? How does Europe help us?’ In the era of personalised medicine, the EU can help in many ways. “Personalised medicine starts with you and me. It’s all about empowering the patient and giving the right treatment to the right one at the right time – in our case for the lung cancer patients. Sound simple? Well, it isn’t, for a variety of reasons, but the concept is already starting to revolutionise medicine and the way treatment is delivered.”

The White Paper notes that “understanding a new diagnosis is frightening and, because treatments are moving so fast due to developments in science, often confusing. Patients need to realise that treatment strategies will depend on the type of lung cancer, what stage it has reached, their general state of health and more. Add to this the treatment options of surgery, radiation therapy, chemotherapy and established or experimental targeted drugs, plus the various possible side-effects and it becomes a minefield”.

“Healthcare workers must play a vital role in empowering the patient to allow him or her to fully understand the circumstances and make choices,” it adds.

With the increased knowledge of the human genome, physicians can analyse a patient’s genetic make-up —with careful consideration to the tumour cells, which can be unique — and target subsequent therapy to treat the individual patient and the individual tumour.

EAPM says personalised medicine allows scientists to investigate a tumour and try to identify genes to predict for drug sensitivity, or genes that may possibly predict patients who will do better and need no further treatment, or those who might benefit from further treatment. In the future, more and more treatment decisions will be based upon the molecular characteristics of an individual tumour. More research could lead to identifying lung cancer earlier, which would increase the cure rates immensely.

Denis Horgan, EAPM executive director, said: “Personalised medicine for patients with non-small-cell lung cancer is already here. For example, pathologists can perform the most complete and accurate sub-typing of tumours possible. “Next-generation sequencing looks set to allow extensive genetic analysis of single samples, although various technical, logistical and ethical problems – Big Data and data protection, for example – need to be solved.”

“Legislators have a huge role to play here, without a doubt,” Cristian Busoi MEP added.

Regine Deniel Ihlen, from Lung Cancer Europe summed it up, saying: “This is crunch time for Europe. The clock is ticking for patients. But there is time. Time that allows us to put the patients at the centre of their own care but it also means prioritisation is the order of the day. “Better health for citizens and patients is essential to Europe’s prosperity. We cannot grow without healthier citizens that can contribute to the Member Sate and the EU project.”

Among the White Paper’s ‘asks’ are the need for an acknowledgement that lung cancer is one of Europe’s biggest killers and that the European Union can play an important role in helping to tackle the disease.

It adds that the EU should put guidelines in place that will allow Member States to set-up quality assured early detection programmes for lung cancer, and that there is a need for increased public-private partnerships, such as IMI II. The Paper also calls for increased collaboration between pharmaceutical researchers to find the best treatments for patients, which will reduce the cost burden for individual companies in developing treatment.

Finally, it says: “Member States and the EU institutions should act together to overcome the barriers to innovation, including recognising the real value of new treatments and making access to them easier, boosting research across Europe, and including all stakeholders – and particularly patients – in policy formation.”

Press release: Lung Cancer White Paper launched (PDF)

LuCE-EU-Policy-Position-Paper 2015 (PDF)


Confronting America’s Smoking Pandemic, Part 1: 1939-1966 | See more at:


ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer (PDF)


MEDIA RELEASE – Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib (PDF)


PRESS RELEASE – Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer (PDF)



Ingelheim, Germany, (27 November 2014) – Today Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for VARGATEF® (nintedanib*), valid for the 28 countries within the EU. VARGATEF® in combination with docetaxel is indicated for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy.

“The approval of nintedanib offers a much needed new treatment option for adult lung cancer patients with advanced adenocarcinoma in the second-line setting,” commented PD. Dr Martin Reck, Head of Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany and lead investigator of the LUME-Lung 1 trial. “The clinical data has shown that patients receiving nintedanib plus docetaxel experienced over one year overall survival with no further compromise to their quality of life, compared to docetaxel alone.”

Adenocarcinoma is the most common type of lung cancer and the majority of patients are diagnosed in an advanced stage.2 Most patients will experience disease progression during or after first-line chemotherapy and there is a significant unmet need for new, effective second-line treatments.3 “We are delighted by the European Commission’s decision to approve VARGATEF® in the EU and feel extremely proud that our long standing commitment to oncology research and development has brought a new option to lung cancer patients with this specific type of disease,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “The approval of VARGATEF® expands our oncology portfolio, following last year’s approval of GIOTRIF® (afatinib) for another specific type of lung cancer. In the idiopathic pulmonary fibrosis indication, nintedanib has recently been approved by the U.S. FDA.”

The approval of nintedanib*, a triple angiokinase inhibitor, is based on the outcomes of the LUME-Lung 1 clinical trial which enrolled 1,314 patients with NSCLC, after first-line chemotherapy.1 Data from the study, published in Lancet Oncology (Feb 2014), demonstrated that compared to docetaxel alone, nintedanib* when added to docetaxel significantly extended median overall survival from 10.3 to 12.6 months (p=0.0359; HR: 0.83) for patients with adenocarcinoma, with a quarter of patients surviving for two years or more (survival at 24 months – nintedanib* plus docetaxel, 25.7% of patients vs. placebo plus docetaxel, 19.1% of patients, p=0.0359; HR: 0.83).1 Nintedanib* demonstrated a manageable adverse event profile without further compromising patients’ overall health-related quality of life.

Adding nintedanib* to docetaxel did not significantly increase discontinuation rates, compared to docetaxel alone.1 Nintedanib* is an oral, twice-daily treatment and is the second approved compound in the Boehringer Ingelheim oncology portfolio. GIOTRIF® (afatinib**) was the first oncology drug from the portfolio to be approved to treat non-small cell lung cancer patients with distinct types of EGFR-mutation positive NSCLC.


  1. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143–55.
  2. Howlader N, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD,, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
  3. Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68: 4774-82



Lung Cancer: We’re Listening – helping us to better understand life with lung cancer

Lung Cancer: We’re Listening is a survey that uses pictures to allow lung cancer patients and family members from around the world to express, share and compare experiences. The information gathered from this survey will be used to improve lung cancer awareness and support services.

If you have lung cancer, or care for a loved one with lung cancer, please click on the link below to complete this short survey and tell us about some of the challenges you may be facing right now– it only takes a few minutes.

Go to to share your experience of life with lung cancer


“Widower re-creates his wedding day photos with three-year-old daughter”: read the article


27th September 2013, Amsterdam: New European association for lung cancer patients launched today

Press Release (Pdf)


Bonnie J. Addario starring at The Steve Harvey Show in USA


From VITAL OPTIONS lNTERNATIONAL Newsletter – Summer 2013: NEW Videos Released From ASCO 2013


Breaking News: The Lung Times Newsletter


Vital Options International – Newsletter – May, 2013


11th Annual National Young Adult Cancer Awareness Week April 1-7, 2013


Lung cancer ‘overtaking breast cancer in European women’


Pfizer’s XALKORI® receives Conditional Marketing Authorization from the European Commission for the treatment of adults with previously treated ALK-Positive Advanced Non-Small Cell Lung Cancer In The EU. Press Release


News from American Society of Clinical Oncology (ASCO)

ASCO: Afatinib Improves PFS, Quality of Life in EGFR Mutation-Positive Lung Cancer

European Medicines Agency boosts EU transparency with online publication of suspected side effect reports

Best practices on civic participation on active ageing policies

Active Citizenship decided to dedicate a project to the 2012 European Year for Active Ageing and Solidarity between Generations. “Best practices on civic participation on Active Ageing policies” directly falls into the 6th European Patients’ Rights Day, which will be celebrated as every year the 18th of April. This fundamental project will be concluded through the Conference “Active Ageing citizens at the center of EU health policy”, to be held in Brussels the 15th – 16th May 2012.

Newsletter from National Lung Cancer Partnership.

National Radon Action Month: January is National Radon Action Month…

Posted by press m d, y No Comments »
Read More

Christmas Market 2015

Mercatini di Natale 2015Christmas Market 2015Marchés de Noël 2015

Posted by press m d, y No Comments »
Read More